Prostate cancer Posts Page 2 on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

What is Neutropenia?

What is Neutropenia?

Posted by on Jan 21, 2018 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 1 comment

There are 1.6 million people diagnosed with cancer in the US each year. Of these, 650,000 receive chemotherapy. Did you know that 60,000 people a year are hospitalized for neutropenia, a common side effect of chemotherapy? One in fourteen die because of it. Of the 650,000 receiving chemotherapy, 104,000 are not aware of neutropenia and 52,000 don’t...

Read More

Emergencies and Illness

Emergencies and Illness

Posted by on Jan 17, 2018 in Blog, Breast cancer, Colorectal cancer, Coronary artery disease, Diabetes mellitus, Hodgkin's lymphoma, Hypertension, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Prostate cancer | 1 comment

After three hurricanes, flooding, fires and mudslides, and now severe cold and snow in the Deep South and throughout the country, the US has had its share of emergencies. Are you prepared? For people who rely on oxygen, who are on dialysis, have diabetes or other serious conditions, it is time to think about putting together some of the essentials.  What...

Read More

Abiraterone acetate and docetaxel with androgen deprivation therapy in high risk and metastatic hormone naive prostate cancer

Posted by on Jan 15, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to find out if androgen deprivation therapy (ADT) is more effective used with docetaxel (Taxotere) or abiraterone (Zytiga). There was no significant difference found between the two treatment options.  Some background Androgen deprivation therapy (ADT) is a treatment used for advanced prostate...

Read More

CAR T-Cells and HIV: What’s the Connection?

CAR T-Cells and HIV: What’s the Connection?

Posted by on Jan 5, 2018 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 1 comment

It has taken decades of work for researchers to find ways to activate the immune system to treat cancer (what we now call immuno-oncology or I-O). Much of that work has been poorly funded. Largely, it has been the result of researchers getting experience in other disciplines (like infectious disease) and then transferring that expertise to oncology...

Read More

Does metformin improve survival rates in patients with prostate cancer?

Posted by on Dec 22, 2017 in Prostate cancer | 0 comments

In a nutshell This study investigated if the use of metformin for anti-diabetic therapy improved survival rates in men also treated for prostate cancer. They found that patients taking metformin may have a greater chance of survival from prostate cancer. Some background Metformin is a medication that is commonly used to lower blood sugar levels...

Read More

Local treatment plus androgen deprivation therapy used as treatment for node-positive prostate cancer.

Posted by on Dec 17, 2017 in Prostate cancer | 0 comments

In a nutshell This study aims to find out if local treatment with or without ADT  is useful in the case of node-positive prostate cancer. This study found that local therapy and androgen deprivation therapy (ADT) is more effective for patients with node-positive prostate cancer than ADT alone.    Some background Local treatment or...

Read More

PTSD and Cancer

PTSD and Cancer

Posted by on Dec 11, 2017 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 2 comments

“I think all too often we underestimate the impact of a cancer diagnosis on the mental health and well-being of the individual, thus it goes unaddressed.” ~Stephanie Zimmerman, MSN Receiving a diagnosis of cancer can bring on feelings of worry, fear, dread, anger, uncertainty and loss.  Research indicates that, for some people, these symptoms of...

Read More

Evaluating active surveillance for intermediate risk prostate cancer as treatment option

Posted by on Dec 9, 2017 in Prostate cancer | 0 comments

In a nutshell This study aimed to evaluate active surveillance as an option in intermediate stage prostate cancer. It found that it should be based on multiple criteria, but is still a viable option. Gleason score, PSA, volume of cancer in biopsy, age, and MRI results should all play a role in making the decision.  Some background Active...

Read More